Presence of exon 5-deleted oestrogen receptor in human breast cancer: Functional analysis and clinical significance

British Journal of Cancer

Volumn 75, Issue 8, 1997, Pages 1173-1184

  Desai, A J ^a   Luqmani, Y A ^b,d   Walters, J E ^a   Coope, R C ^a   Dagg, B ^a   Gomm, J J ^a   Pace, P E ^a   Rees, C N ^a   Thirunavukkarasu, V ^a   Shousha, S ^a   Groome, N P ^b   Coombes, R ^a   Ali, S ^a,c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b OXFORD BROOKES UNIVERSITY   (United Kingdom)

^c Charing Gross Westminster Med Sch   (United Kingdom)

^d KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Breast neoplasm; Exon; Oestrogen receptor; Polymerase chain reaction; Transcription

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GENETICS; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL STRAIN MCF 7; CLINICAL FEATURE; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSACTIVATION;

EID: 8044242323     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.202     Document Type: Article

References (48)

1. Aldwin L and Nitecki DE (1987) A water soluble, monitorable peptide and protein crosslinking agent. Anal Biochem 164: 494-501
2. Ali S, Metzger D, Bornerl J-M and Chambon P (1993a) Phosphorylation of the human oestrogen receptor; identification of a phosphorylation site required for trans-activation. EMBO J 12; 1153-1160
3. Ali S, Lutz Y, Bellocq J-P. Chenard-Neu M-P, Rouyer N and Metzger D (1993b) Production and characterisation of monoclonal antibodies recognising defined regions of the human oestrogen receptor. Hybridoma 12; 391-405
4. Atherton E and Sheppard RC (1985) Solid phase peptide synthesis using N. fluorenyl methocarboxycarbonyl amino-acid penta fluorophenyl esters. J Chem Soc Chem Commun 15; 165-166
5. Bansal GS, Yiangou C, Coope RC, Gomm J, Johnston C, Coombes RC and Luqmani YA (1995) Expression of fibroblast growth factor 1 in human breast. Br J Cancer 72: 1420-1426
6. Barrett-Lee PJ, Travis M, McClelland RA, Luqmani Y and Coombes RCC (1987) Characterisation of estrogen receptor messenger RNA in human breast cancer. Cancer Res 47: 6653-6659
7. Berry M, Metzger D and Chambon P (1990) Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9: 2811-2818
8. Burgess HE and Shousha S (1993) An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia. J Pathol 170; 37-43
9. Daffada AI. Johnston SRD, Smith IE, Detre S, King N and Dowsett M (1995) Exon 5 deletion variant estrogen receptor messenger RNA in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 55; 288-293
10. Dotzlaw H, Alkhalaf M and Murphy I.C (1992) Characterisation of estrogen receptor variant mRNAs from human breast cancer. Mol Endocrinol 6; 773-785
11. Foekens JA, Van-Putten WI., Portengen H, De-Koning HY, Thirion B, Alexieva-Figusch J and Klijn JG (1993) Prognostic value of PS2 and cathepsin D in 710 human primary breast tumours: multivariate analysis. J Clin Oncol 11: 899-908
12. Foster BD, Cavener DR and Parl FF (1991) Binding analysis of the estrogen receptor to its specific DNA target site in human breast cancer. Cancer Res 51; 3405-3410
13. Fuqua Saw (1994) Estrogen receptor mutagenesis and hormone resistance. Cancer 74: 1026-1029
14. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW and McGuire WL (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105-109
15. Fuqua SAW, Fitzgerald SD, Allred C, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW and McGuire WL (1992) Inhibition of estrogen receptor action by a naturally occuring variant in human breast tumors. Cancer Res 52; 483-486
16. Galfre G and Milstein C (1987) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 73: 3-36
17. Green S and Chambon P (1987) Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. Nature 325: 75-78
18. Green S, Walter P, Kumar V, Krust A, Bornerl J-M, Argos P and Chambon P (1986) Human estrogen receptor cDNA: sequence, expression and homology to v-erbA. Nature 320: 134-139
19. Harlow E and Lane D (1988) Antibodies: A Laboratory Manual. pp. 553-613, Cold Spring Harbor Laboratory Press: New York
20. Horwitz KB (1994) How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol 49; 295-302
21. King DS, Fields CG and Fields GB (1990) A cleavage method which minimizes side reactions following Finoc solid phase peptide synthesis. Int Peptide Protein Res 36; 255-266
22. Krust A, Green S, Argos P, Kumar V, Walter P, Bornert J-M and Chambon P (1986) The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J 5; 891-897
23. Kumar V, Green S, Staub A and Chambon P (1986) Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J 5: 2231-2236
24. Kumar V, Green S, Stack G, Berry M, Jin JR and Chambon P (1987) Functional domains of the human oestrogen receptor. Cell 51; 941-951
25. Lachmann PJ, Strangeways L, Vgakurum A and Evans Gl (1986) In Synthetic Peptides as Antigens. Ciba Symposium V 119 pp. 25-40, Wiley: Chichester
26. Lees JA, Fawell SE and Parker MG (1989) Identification of two trans-activation domains in the mouse oestrogen receptor. Nucleic Acids Res 17; 5477-5488
27. Lehrer S, Sanchez M, Song HK, Dalton J, Levine E, Savorelti P, Thung SN and Schachter B (1990) Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer. Lancet 335: 622-624
28. Lehrer S, Rabin J, Kalir T and Schachter BS (1992) Estrogen receptor variant and hypertension in women. Hypertension 21: 439-441
29. McCullough KC and Spier RE (1990) Monoclonal Antibodies in Biotechnology: Theoretical and Practical Aspects. pp. 258-261. Cambridge University Press: Cambridge, UK
30. McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433
31. McGuire WL, Chamness GC and Fugua SAW (1991) Estrogen receptor variants in clinical breast Cancer. Mol Endocrinol 5: 1571-1577
32. Metzger D, Ali S, Bornert JM and Chambon P (1995) Characterization of the amino-terminal transcriptional activation Function of the human estrogen receptor in animal and yeast cells. J Biol Chem 270; 9535-9542
33. Montano MM, Muller V, Trobaugh A and Katzenellenbogen BS (1995) The carboxy-terminal F domain of the human estrogen receptor; role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9: 814-825
34. Morrison CA, Fishleigh RV, Ward DJ and Robson B (1987) Computer aided design and physiological testing of lutenisíng hormone-releasing hormone analogue for 'adjuvant free' immunocastration. FEBS Lett 214: 65-70
35. Murphy LC (1990) Estrogen receptor variants in human breast cancer. Mol Cell Endocrinol 74: C83-C86
36. Ponglikitmongkol M, Green S and Chambon P (1988) Genomic organisation of the human oestrogen receptor gene. EMBO J 7: 3385-3388
37. Ravdin PM, Green S, Dorr TM, McGuire WL. Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B and Osborne CK (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291
38. Rea D and Parker MG (1996) Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res 56: 1556-1563
39. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: a Laboratory Manual. pp. 7.19-7.22. Cold Spring Harbor Laboratory Press: New York
40. Sannino P and Shousha S (1994) Demonstration of oestrogen receptors in paraffin wax sections of breast carcinoma using the monoclonal antibody 1D5 and microwave oven processing. J Clin Pathol 47: 90-92
41. Scott GK, Kushner P, Vigne J-L and Benz CC (1991) Truncated forms of DNA binding estrogen receptors in human breast cancer. J Clin Invest 88: 700-706
42. Sluyser M (1994) Role of estrogen receptor variants in the development of hormone resistance in breast cancer. Clin Biochem 25; 407-414
43. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB and Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056-1061
44. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E and Chambon P (1989a) The human estrogen receptor has two independent nonacidic transcriptional activation functions, Cell 59: 477-487
45. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I and Chambon P (1989b) The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8: 1981-1986
46. Wang Y and Miksicek RJ (1991) Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 5: 1707-1715
47. Webster NJG, Green S, Jin JR and Chambon P (1988) The hormone binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function Cell 54; 199-207
48. Zhang Q-X, Borg A and Fuqua SAW (1993) An exon 5 deletion variant of the estrogen receptor frequently co-expressed with wild-type estrogen receptor in human breast cancer. Cancer Res 53: 5882-5884